Patents by Inventor Kai Sinervo

Kai Sinervo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TASIPIMIDINE FORMULATIONS AND USE THEREOF
    Publication number: 20240173254
    Abstract: The present disclosure relates to a pharmaceutical composition in the form of an orally deliverable liquid composition comprising tasipimidine, or a pharmaceutically acceptable salt thereof, as an active ingredient and to the use thereof in the treatment and prevention of a disorder, condition or disease where an alpha2A agonist is indicated to be useful, for example, for use as a sedative or analgesic agent, and for use in the treatment of anxiety or agitation. The composition is stable at the pH range from about 2.0 to about 5.0.
    Type: Application
    Filed: March 18, 2022
    Publication date: May 30, 2024
    Inventors: Johanna KUJALA, Jenni LEHTISALO, Jukka SALMIA, Kai SINERVO
  • TASIPIMIDINE FORMULATIONS AND USE THEREOF
    Publication number: 20240165083
    Abstract: The present disclosure relates to a pharmaceutical composition in the form of an orally deliverable liquid composition comprising tasipimidine, or a pharmaceutically acceptable salt thereof, as an active ingredient and to the use thereof in the treatment and prevention of situational anxiety and fear in companion animals, such as dogs. The composition is stable at the pH range from about 2.0 to about 5.0 and it can be easily administered by the pet owners.
    Type: Application
    Filed: March 18, 2022
    Publication date: May 23, 2024
    Inventors: Johanna KUJALA, Jenni LEHTISALO, Jukka SALMIA, Kai SINERVO
  • NOVEL SALT FORMS OF A 4H-PYRAN-4-ONE STRUCTURED CYP11A1 INHIBITOR
    Publication number: 20240158377
    Abstract: The present invention relates to novel salts, particularly crystalline salts, of 2-(isoindolin-2-ylmethyl)-5-((1-(methyl sulfonyl)piperidin-4-yl)methoxy)-4H-pyran-4-one (I) which are particularly suitable for use in the manufacture of pharmaceutical 5 compositions. Furthermore, the invention relates to pharmaceutical compositions comprising such novel salts. Compound (I) is a selective inhibitor of CYP11A1 enzyme and is useful in the treatment of hormonally regulated cancers, such as prostate cancer and breast cancer.
    Type: Application
    Filed: February 28, 2022
    Publication date: May 16, 2024
    Applicant: Orion Corporation
    Inventors: Oskari Karjalainen, Mikko Mäkelä, Mihaela Pop, Petteri Rummakko, Anna Shevchenko, Kai Sinervo, Eija Tiainen